Unknown

Dataset Information

0

KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial.


ABSTRACT: KN046, a bispecific antibody targeting PD-L1 and CTLA-4, presents a promising therapeutic option for metastatic non-small cell lung cancer (NSCLC). In this multicenter phase 2 trial, patients with nonsquamous (non-sq) NSCLC receive pemetrexed, whereas those with sq-NSCLC receive paclitaxel, plus KN046 and carboplatin. Following four cycles, maintenance therapy includes KN046 with pemetrexed for non-sq-NSCLC and KN046 for sq-NSCLC. The objective response rate is 46.0%, and the median duration of response is 8.1 months. The median progression-free and overall survival are 5.8 and 26.6 months, respectively. The common adverse events include anemia (87.4%), loss of appetite (72.4%), and neutropenia (70.1%). The most prevalent immune-related adverse event is pruritus (28.7%). These findings indicate that first-line treatment with KN046 and chemotherapy is effective and tolerable in metastatic NSCLC patients, warranting further investigation in a larger phase 3 trial. The trial is registered at ClinicalTrials.gov (NCT04054531).

SUBMITTER: Zhao Y 

PROVIDER: S-EPMC10983105 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

KN046, a bispecific antibody against PD-L1 and CTLA-4, plus chemotherapy as first-line treatment for metastatic NSCLC: A multicenter phase 2 trial.

Zhao Yuanyuan Y   Chen Gang G   Li Xingya X   Wu Jingxun J   Chang Baoping B   Hu Sheng S   Yang Shujun S   Xu Ting T   Liu Yilan Y   Wang Ni N   Zhang Li L   Huang Yan Y  

Cell reports. Medicine 20240301 3


KN046, a bispecific antibody targeting PD-L1 and CTLA-4, presents a promising therapeutic option for metastatic non-small cell lung cancer (NSCLC). In this multicenter phase 2 trial, patients with nonsquamous (non-sq) NSCLC receive pemetrexed, whereas those with sq-NSCLC receive paclitaxel, plus KN046 and carboplatin. Following four cycles, maintenance therapy includes KN046 with pemetrexed for non-sq-NSCLC and KN046 for sq-NSCLC. The objective response rate is 46.0%, and the median duration of  ...[more]

Similar Datasets

| S-EPMC11806070 | biostudies-literature
| S-EPMC10838317 | biostudies-literature
| S-EPMC10254625 | biostudies-literature
| S-EPMC7050096 | biostudies-literature
| S-EPMC10309553 | biostudies-literature
| S-EPMC11885889 | biostudies-literature
| S-EPMC11624766 | biostudies-literature
| S-EPMC10882294 | biostudies-literature
| S-EPMC9119358 | biostudies-literature
| S-EPMC5720992 | biostudies-literature